Commentaries
Pulsed dye laser treatment of superficial basal cell carcinoma
First published: 16 March 2015
No abstract is available for this article.
References
- 1Bath-Hextall F, Ozolins M, Armstrong SJ et al. Surgical excision versus 5% imiquimod cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 96–105.
- 2Konnikov N, Avram M, Jarell A et al. Basal cell carcinomas: response and follow up 12–21 months after treatment. Lasers Surg Med 2011; 43: 72–8.
- 3Tran HT, Lee RA, Oganesyan G et al. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med 2012; 44: 459–67.
- 4Karsai S, Friedl H, Buhck H et al. The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial. Br J Dermatol 2015; 172: 677–83.
- 5Gay-Crosier F, Polla LL, Tschopp J, Schifferli JA. Complement activation by pulsed tunable dye laser in normal skin and hemangioma. J Invest Dermatol 1990; 94: 426–31.
- 6Omi T, Kawana S, Satp S et al. Cutaneous immunological activation elicited by a low-fluence pulsed dye laser. Br J Dermatol 2005; 153(Suppl. 2): 57–62.
